on November 4, 2004
Published online before print November 4, 2004, doi: 10.1161/01.STR.0000148237.13659.e6
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 1, 2004
From the Department of Neurosurgery (R.N., S.K., T.I., K.H., Y.I.), Hokkaido University Graduate School of Medicine, Japan. * To whom correspondence should be addressed. E-mail: skuroda{at}med.hokudai.ac.jp.
Background and Purpose--The etiology of moyamoya disease still remains unknown. This study was aimed to explore the role of hepatocyte growth factor (HGF), a strong inducer of angiogenesis, in development of moyamoya disease. Methods--We studied cerebrospinal fluid (CSF) from 39 patients with moyamoya disease (24 children and 15 adults), 6 control patients with cervical spondylosis, and 7 control patients with internal carotid artery occlusion. CSF level of HGF was determined by enzyme-linked immunosorbent assay technique. We also evaluated the distribution of HGF and its cellular receptor c-Met in the carotid fork obtained from 2 patients with moyamoya disease and 2 control patients. Results--CSF level of HGF was 408.2±201.6 pg/mL and 443.2±193.5 pg/mL in patients with cervical spondylosis and internal carotid artery occlusion, respectively (mean±SD). On the other hand, CSF level of HGF was 820.3±319.0 pg/mL in patients with moyamoya disease, being significantly higher than those in 2 control groups (P<0.01). Both HGF and c-Met were widely distributed in the media and thickened intima of the carotid fork in patients with moyamoya disease but not in control patients. Conclusions--This study revealed that HGF is densely found in the carotid fork, and its CSF level is markedly elevated in moyamoya disease, suggesting that HGF may be a key protein for pathogenesis of moyamoya disease.
Revised on September 2, 2004
Accepted on October 4, 2004
Increased Expression of Hepatocyte Growth Factor in Cerebrospinal Fluid and Intracranial Artery in Moyamoya Disease
Rina Nanba MD, PhD;
Key words: angiogenesis • hepatocyte growth factor • moyamoya disease • protooncogene protein c-met
This article has been cited by other articles:
 |
|
 |
|
  R. M. Scott and E. R. Smith Moyamoya Disease and Moyamoya Syndrome N. Engl. J. Med., March 19, 2009; 360(12): 1226 - 1237. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kuroda, N. Hashimoto, T. Yoshimoto, Y. Iwasaki, and for the Research Committee on Moyamoya Disease in Radiological Findings, Clinical Course, and Outcome in Asymptomatic Moyamoya Disease: Results of Multicenter Survey in Japan Stroke, May 1, 2007; 38(5): 1430 - 1435. [Abstract] [Full Text] [PDF]
|
|